Preclinical evidence consistently supports GLP-1 RA efficacy for substance use disorders, observational human data is promising, and RCTs are emerging—but safety, dosing, and mechanisms need clarification.
Consistent across substancesGLP-1 drugs reduce addictive behaviors for alcohol, nicotine, opioids, and psychostimulants in preclinical models
What the researchers found
Preclinical evidence consistently supports GLP-1 RA efficacy across alcohol, nicotine, opioid, and psychostimulant use disorders. Observational human data suggest benefits. RCTs are emerging with promising but mixed signals. No increased psychopathology risk.
Why it matters
Addiction causes enormous human suffering with few effective medications. GLP-1 drugs are already widely available and could be rapidly repurposed if RCTs confirm efficacy.
How the study worked
Narrative review of preclinical models, observational cohort studies, emerging RCTs, and pharmacovigilance data on GLP-1 therapies for substance use and mental health disorders.
What this study cannot tell us
Very limited RCT data. Most human evidence is observational. Optimal dose, duration, and individual predictors of response unknown. Mechanisms not fully understood.
How to read the evidence
Narrative review integrating preclinical, observational, and limited RCT evidence. Strong rationale with emerging but not yet definitive clinical proof.
When this study was published
Published in 2025, at a pivotal time for GLP-1 addiction research.
The bigger picture
The GLP-1 system's involvement in both metabolism and reward processing positions these drugs at the intersection of two major public health crises: metabolic disease and addiction.
Questions still open
- Which ongoing RCTs are most likely to demonstrate GLP-1 efficacy for addiction?
- Will GLP-1 drugs show different efficacy across different substances of abuse?
- How can equitable access to GLP-1 addiction treatment be ensured?
Common questions
Can GLP-1 drugs like Ozempic help with addiction?
Do GLP-1 drugs cause depression or suicidal thoughts?
Read the original research
Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.
JAMA psychiatry, 83(3), 306-314
Citation
Farokhnia, Mehdi; Leggio, Lorenzo. (2026). Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.. JAMA psychiatry, 83(3), 306-314. https://doi.org/10.1001/jamapsychiatry.2025.4308